Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Apr 09, 2015	Evoke Pharma Granted European Union Formulation Patent for EVK-001 SOLANA BEACH, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the European Patent Office has granted the Company European Union (EU) patent no.	View HTML Evoke Pharma Granted European Union Formulation Patent for EVK-001 14.9 KB
Toggle Summary Apr 14, 2015	Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001 Manufacturing Program Includes Three Year Registration Stability Data	View HTML Evoke Pharma Achieves Significant Manufacturing Milestone With Successful Completion of Commercial Scale Production of EVK-001 17 KB
Toggle Summary Apr 30, 2015	Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results SOLANA BEACH, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the first quarter of 2015 on Thursday, May 14, 2015,	View HTML Evoke Pharma Schedules Webcast and Conference Call for First Quarter 2015 Financial Results 11.8 KB
Toggle Summary May 14, 2015	Evoke Pharma Reports First Quarter 2015 Results Company Begins Preparation for Commercialization of EVK-001	View HTML Evoke Pharma Reports First Quarter 2015 Results 26.3 KB
Toggle Summary Jun 24, 2015	Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis Second Phase 2 Trial Demonstrates Effectiveness of Intranasal Metoclopramide Spray	View HTML Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 18.8 KB
Toggle Summary Jul 01, 2015	Evoke Pharma to Present at Cantor Fitzgerald Inaugural Healthcare Conference SOLANA BEACH, Calif. , July 1, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, will host an investor presentation on Wednesday, July 8, 2015 at 10:15 AM ET at the Cantor Fitzgerald Inaugural	View HTML Evoke Pharma to Present at Cantor Fitzgerald Inaugural Healthcare Conference 14.8 KB
Toggle Summary Jul 30, 2015	Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results SOLANA BEACH, Calif. , July 30, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2015 on Thursday, August 13,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2015 Financial Results 13 KB
Toggle Summary Aug 13, 2015	Evoke Pharma Reports Second Quarter 2015 Results Enrolled 130 total subjects in Phase 3 clinical trial through end of July Recent FDA draft guidance of advice on Gastroparesis mirrors Evoke's Phase 3 clinical trial protocol design SOLANA BEACH, Calif. , Aug. 13, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.	View HTML Evoke Pharma Reports Second Quarter 2015 Results 28.6 KB
Toggle Summary Aug 18, 2015	Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's	View HTML Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 16.6 KB
Toggle Summary Sep 15, 2015	U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs	View HTML U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 18.7 KB